舒更葡糖钠用于肾衰竭患者神经肌肉阻滞的逆转
Sugammadex for Reversal of Neuromuscular Blockade in a Patient With Renal Failure.
作者信息
Pfaff Kayla, Tumin Dmitry, Tobias Joseph D
出版信息
J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):238-241. doi: 10.5863/1551-6776-24.3.238.
Abstract
Residual neuromuscular blockade following the use of non-depolarizing neuromuscular blocking agents (NMBAs) can lead to postoperative respiratory complications, including oxygen desaturation, atelectasis, and pneumonia. Sugammadex rapidly reverses steroidal NMBAs by encapsulating them in a highly stable water-soluble complex. This NMBA-sugammadex complex then undergoes renal elimination. In patients with renal insufficiency or failure, concern has been expressed regarding the elimination of the NMBA-sugammadex complex. We present a 19-year-old patient with renal failure who received sugammadex for reversal of neuromuscular blockade. The use of sugammadex in patients with renal dysfunction is discussed and safety concerns are reviewed.
摘要
使用非去极化神经肌肉阻滞剂（NMBAs）后残留的神经肌肉阻滞可导致术后呼吸并发症，包括氧饱和度下降、肺不张和肺炎。舒更葡糖通过将甾体类NMBAs包裹在高度稳定的水溶性复合物中，迅速逆转其作用。然后，这种NMBA-舒更葡糖复合物经肾脏排泄。对于肾功能不全或衰竭的患者，人们对NMBA-舒更葡糖复合物的排泄表示担忧。我们报告了一名19岁的肾衰竭患者，其接受舒更葡糖以逆转神经肌肉阻滞。本文讨论了舒更葡糖在肾功能不全患者中的应用，并对安全性问题进行了综述。
相似文献
1
Sugammadex for Reversal of Neuromuscular Blockade in a Patient With Renal Failure.
J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):238-241. doi: 10.5863/1551-6776-24.3.238.
2
Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Anesth Analg. 2010 Apr 1;110(4):1239. doi: 10.1213/ANE.0b013e3181ce8d5e.
3
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD007362. doi: 10.1002/14651858.CD007362.pub2.
4
Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal.
Drugs Today (Barc). 2012 Jun;48(6):405-13. doi: 10.1358/dot.2012.48.6.1813474.
5
Myasthenia gravis and sugammadex: A case report and review of the literature.
Saudi J Anaesth. 2020 Apr-Jun;14(2):244-248. doi: 10.4103/sja.SJA_721_19. Epub 2020 Mar 5.
6
Sugammadex use in pediatric patients with stage IV-V chronic kidney disease in a quaternary referral hospital: a case series.
BMC Anesthesiol. 2024 Jun 10;24(1):206. doi: 10.1186/s12871-024-02584-9.
7
Recovery of muscle function after deep neuromuscular block by means of diaphragm ultrasonography and adductor of pollicis acceleromyography with comparison of neostigmine vs. sugammadex as reversal drugs: study protocol for a randomized controlled trial.
Trials. 2018 Feb 21;19(1):135. doi: 10.1186/s13063-018-2525-7.
8
Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use.
Minerva Anestesiol. 2013 Jun;79(6):661-6. Epub 2012 Nov 29.
9
Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.
Clin Interv Aging. 2017 Dec 22;13:13-24. doi: 10.2147/CIA.S134108. eCollection 2018.
10
Neuromuscular blockade management for intraoperative neural monitoring.
Kaohsiung J Med Sci. 2020 Apr;36(4):230-235. doi: 10.1002/kjm2.12153. Epub 2019 Nov 12.
引用本文的文献
1
Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Medicina (Kaunas). 2021 Nov 17;57(11):1259. doi: 10.3390/medicina57111259.
2
Sugammadex use in patients with end-stage renal disease: a historical cohort study.
Can J Anaesth. 2020 Dec;67(12):1789-1797. doi: 10.1007/s12630-020-01812-3. Epub 2020 Sep 18.
3
Evaluation of the Toxicity of Sugammadex in Zebrafish Larvae.
J Korean Med Sci. 2020 Mar 9;35(9):e51. doi: 10.3346/jkms.2020.35.e51.
本文引用的文献
1
Sugammadex to reverse neuromuscular blockade in a child with a past history of cardiac transplantation.
Ann Card Anaesth. 2017 Jul-Sep;20(3):376-378. doi: 10.4103/aca.ACA_15_17.
2
Rocuronium vs. succinylcholine for rapid sequence intubation: a Cochrane systematic review.
Anaesthesia. 2017 Jun;72(6):765-777. doi: 10.1111/anae.13903.
3
Current evidence for the use of sugammadex in children.
Paediatr Anaesth. 2017 Feb;27(2):118-125. doi: 10.1111/pan.13050. Epub 2016 Nov 17.
4
Effects of Sugammadex and Neostigmine on Renal Biomarkers.
Med Sci Monit. 2016 Mar 10;22:803-9. doi: 10.12659/msm.897608.
5
The use of rocuronium and sugammadex in paediatric renal transplantation: Two case reports.
Eur J Anaesthesiol. 2016 May;33(5):383-6. doi: 10.1097/EJA.0000000000000338.
6
Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial.
Eur J Anaesthesiol. 2015 Oct;32(10):681-6. doi: 10.1097/EJA.0000000000000312.
7
Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment.
Br J Anaesth. 2015 May;114(5):777-84. doi: 10.1093/bja/aet586. Epub 2015 Mar 31.
8
Rapid sequence intubation: What does it mean? Does it really matter?
Saudi J Anaesth. 2014 Apr;8(2):153-4. doi: 10.4103/1658-354X.130672.
9
Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome.
Indian J Anaesth. 2013 Jan;57(1):46-51. doi: 10.4103/0019-5049.108562.
10
The limits of succinylcholine for critically ill patients.
Anesth Analg. 2012 Oct;115(4):873-9. doi: 10.1213/ANE.0b013e31825f829d. Epub 2012 Jul 4.
Zotero 插件